Q1 2026 earnings prep — May 8, 2026
One-page watchlist for the May 8 Q1 2026 conference call. Purpose: turn the call from a passive listen into a structured set of yes/no tests against the thesis-confidence model. Pre-call composite: 62% (weighted sum of factors in
site/src/data/thesis_confidence.json). All comparable Q1 2025 specifics that were not in the KB are flagged TBD; verbatim Q4 2025 (Mar 5 2026) and Q3 2025 (Nov 25 2025) call quotes pulled fromkb/05_financials/earnings_calls.md.
The five tests (mapped to thesis-confidence factors)
1. Stage-3 → Stage-4 conversion (weight 30% / pSuccess 55%)
- Listen for:
- “Stage 4” or “production order” or “purchase order” — any of these uttered re: an existing Stage-3 customer is the headline event
- “Named” / specific company name disclosure for any of the four Fortune Global 500 customers (currently all unnamed)
- “Tier-1” coupled to a binding-commitment verb (“signed,” “executed,” “ordered”)
- Cycle-time language: shortening of the published 12–18 month Stage-3 → Stage-4 window for any cohort member
- Foundry-side end-customer pairings (e.g., “Tower customer X has begun PDK integration”)
- Threshold to upgrade to high (75%+): named F500 counterparty plus production-volume PO terms disclosed in 8-K or call (matches the pSuccess trigger language verbatim).
- Threshold to downgrade to low (30%): all four Stage-3 customers reaffirmed without movement, AND no incremental Stage-3 add in Q1 2026 vs. the four-customer count exiting Q4 2025.
- Comparable Q4 2025 quote (Mar 5 2026): “[The] design win cycle matured meaningfully” — LeMaitre. And from Nov 25 2025: “Based on the typical design-win cycle timeline and our current engagement, I expect our first production revenues to happen in 2027. Any revenues in 2026 will come from prototypes or engineering programs.”
2. Telcordia 2000h length-swept reliability pass — ✓ ALREADY PASSED (weight 20% / pSuccess 95%)
Status update (post-prep): the 2,000h length-swept (85/85 damp-heat) pass was disclosed Apr 13-15 (Thompson at IEEE SiPhotonics 2026, Ottawa) and Apr 22 (Blum keynote at PIC International 2026, Brussels) — V_π stable across 25 µm / 500 µm / 1 mm device lengths. This factor moved from “pending mid-2026” to “passed” before Q1 earnings. pSuccess re-rated 85% → 95% on
thesis_confidence.json(2026-04-22).
- What’s still in play on the call:
- Independent third-party validation language (a foundry partner reliability report would re-rate to 99%)
- Foundry-run reliability test on chips returned in Q2 2026 (Tier-1 #1 chips per Mar 5 disclosure)
- Any failure-mode discovery on a length-swept arm post-Apr disclosure (would cut to 70%)
- Comparable Mar 5 2026 quote: Tape-out at SilTerra/Luceda is “intended to validate key design and performance parameters for 200G and 400G modulators… with most test results expected by mid-2026.”
3. First commercial revenue >$1M/quarter (weight 20% / pSuccess 45%)
- Listen for:
- The actual Q1 2026 revenue print (the most load-bearing single number on the call)
- Segment commentary: materials sales vs. NRE vs. license — any breakout would be net-new
- “Repeat” / “recurring” language re: a customer paying twice in the same FY
- Any 2026 revenue range / guidance (LeMaitre has historically declined; any change is signal)
- Threshold for “constructive”: Q1 2026 revenue >$300K (would be ~4× Q1 2025’s $23K and >FY2024’s $96K in a single quarter).
- Threshold for “concerning”: Q1 2026 revenue <$50K (would suggest the FY2025 ramp was front-loaded).
- Comparable Nov 25 2025 quote: “I expect our first production revenues to happen in 2027. Any revenues in 2026 will come from prototypes or engineering programs.” — LeMaitre. And Mar 5 2026: “2026 revenue is expected to be driven primarily by material supply and NRE activity. Volume production and licensing revenues are not anticipated until 2027 at the earliest.”
4. No dilutive raise before commercial revenue (weight 15% / pSuccess 65%)
- Listen for:
- Cash balance at 3/31/2026 — anchor vs. $69M at YE 2025
- “ATM” / “shelf” — any commentary re: the Apr 21 2026 amended $51.4M shelf ($49.3M still available)
- “Funded beyond December 2027” — exact reaffirmation language; any softening is a flag
- Operating cash burn for Q1 — anchor vs. ~$5M/quarter base case
- Threshold to upgrade to 80%: clean quarter (zero ATM draws under amendment) with cash >$60M and runway language reaffirmed.
- Threshold to break thesis: ATM tranche >$20M in Q1 alone without a corresponding revenue inflection (matches the trigger in
thesis_confidence.json). - Comparable Mar 5 2026 quote: “Year-end 2025 cash approximately $69 million… roughly double the $34.9 million reported at the end of the third quarter.” Company “is funded beyond December 2027.” — LeMaitre.
5. Patent / IP moat holds (weight 15% / pSuccess 90%)
- Listen for:
- Any PTAB challenge mention, IPR petition, or “freedom to operate” question from Q&A
- New issued-patent announcements (continuation chains run 2038–2042 per KB)
- Customer / foundry licensee terms language
- Reference to the 2029-03-08 foundational patent expiration — silence is fine; defensiveness is a signal
- Threshold to upgrade: new continuation grant disclosed and tied to a foundry PDK lock-in.
- Threshold to downgrade to 50%: adverse PTAB ruling, competitor invalidates a core composition claim, or a customer-flagged FTO concern surfaced in Q&A.
- Comparable quote: None directly from Mar 5 2026 prepared remarks (IP not a featured topic). Last KB baseline: 2026-04-27, no challenges.
KPI deltas to watch
| Metric | Q4 2025 | Constructive | Concerning |
|---|---|---|---|
| Revenue (quarterly) | ~$160K (FY $237K) | Q1 >$300K (>4× Q1 2025 $23K) | Q1 <$50K |
| Net loss | ~$5.7M | Flat to lower (≤$5.7M) | >$7M |
| Cash | $69M (12/31/2025) | >$60M (no full ATM draw) | <$50M |
| Shares O/S | 148.83M (filing) / 150.61M (proxy 4/6/2026) | <151M | >153M |
| ATM headroom drawn (under Apr 21 amendment) | $0 of new $16.4M incremental | $0 (clean quarter) | Full $16.4M used or more |
| Stage-3 customers | 4 (3 named in 2025 + 1 added Q1 2026) | 5+ | <4 (loss of any) |
| Operating cash burn | ~$5M/Q | ≤$5M/Q | >$6M/Q |
| Foundries with active agreements | 4 | 5+ | <4 |
Language watchlist
Lebby-vs-LeMaitre cadence change: Lebby’s 2024 calls were diffuse (“in progress,” “next 6–9 months,” removed SAM/SOM charts). LeMaitre’s three calls (Mar 13 2025, Nov 25 2025, Mar 5 2026) are direct and metric-driven — he commits to numbers (“about 15 in Stages 1 or 2,” “first production revenues 2027”) and explicitly flags uncertainty (“entry into stage three… is only provisional”). The May 8 call is the fourth LeMaitre-led data point. Look for further tightening of metric specificity, not loosening.
Phrases to count or note in the live transcript:
- Frequency of “stage 4” / “production” / “purchase order” / “named customer” — zero is the YTD baseline; any non-zero is signal
- “Tier-1” coupled to a verb of commitment (“signed,” “executed,” “ordered”)
- Mentions of Marvell (Polariton acquisition closed Apr 22 2026 — any LWLG comment is net-new) or Polariton itself
- Foundry roll-call: Tower (added Mar 11 2026), GlobalFoundries / AMF, AMF by itself, SilTerra (tape-out per Mar 5), Luceda — any with a quantitative update (wafer count, customer count, PDK integration milestone)
- “Funded” / “runway” — any softening from “beyond December 2027” is a dilution flag
- “Custom Perkinamine variant” — Tier-1 #2 CPO program milestone language
- “PDK” — co-design / IP-licensing path proxy; frequency >2025 average is constructive
ATM-draw test
Pre-call baseline:
- Shares O/S 12/31/2025 (10-K filing date): 148,831,122
- Shares O/S 4/6/2026 (DEF 14A record date): 150,610,710
- Delta Q1 2026: +1,779,588 shares (~1.2% dilution between YE and proxy record date)
Per Apr 21 2026 8-K, the Roth ATM was amended to a $51.4M shelf with $49.3M still available; the prior $35M shelf had been ~85% drawn (8M+ shares for $35M gross). The $16.4M of incremental headroom is what’s freshly available.
Decision arithmetic:
- If 10-Q reports shares O/S >151M as of 3/31/2026, the new $16.4M headroom was tapped in Q1 (alongside year-end legacy ATM completion). At an assumed $10/sh average, that’s ~1.6M incremental shares = ~1.1% additional dilution off the 150.6M proxy base.
- If 10-Q reports shares O/S <151M, the amendment is dry powder — clean quarter.
- At 4/24/2026 close of $12.67, $49.3M of full ATM headroom = ~3.9M shares = ~2.6% maximum dilution remaining before a fresh raise would be needed.
Bear read: Aggressive ATM use during the rally signals management views current price as a ceiling, not a floor — and that they don’t expect a near-term Stage-4 catalyst that would lift the price further.
Bull read: Disciplined ATM use at premium pricing converts dilution into 18+ months of additional runway at favorable terms; LeMaitre’s cadence is “intelligent and timely deployment of capital” (Nov 25 2025 verbatim).
Comparable Q1 2025 reference
| Metric | Q1 2025 |
|---|---|
| Revenue | $23K |
| Net loss | ~$5.0M |
| EPS | ~$0.04 |
| Shares O/S (period-end) | ~127M |
| Cash (period-end) | ~$25M |
| Stated runway | ”Through April 2026” (per YE2024 10-K) |
| Stage-3 customers | 0 (first announced Nov 4 2025) |
| Notable | First quarter under LeMaitre as full-year CEO; corporate update via Mar 13 2025 special call (no formal earnings call) |
| Verbatim management quote (Mar 13 2025 special call) | “data center part of [Nvidia’s] revenues is expected to reach 115 billion U.S. dollars” — LeMaitre, citing market sizing |
Base-case test for “trajectory hold”: Q1 2026 revenue ≥ Q1 2025’s $23K, with Stage-3 customer count maintained at 4 and operating cash burn ≤Q1 2025’s ~$5M. Any of these three reversing is a yellow flag; all three reversing is a thesis re-rate event.
Pre-call decision matrix
| Pre-call composite | Post-call updates to … | … if |
|---|---|---|
| 62% | 75%+ | First Stage-4 PO disclosed (named or unnamed F500); OR independent third-party reliability validation of the Apr 22 2,000h pass; OR Q1 revenue >$500K with named NRE customer |
| 62% | 70% | Stage-3 count rises to 5 (incremental add disclosed); Q1 revenue >$300K; no ATM draw |
| 62% | 62% (hold) | Reaffirm 4 Stage-3 customers, “2027 production revenue,” cash >$60M, modest Q1 revenue $100–$300K |
| 62% | 50% | Q1 revenue <$100K AND ATM tapped fully ($16.4M+); OR runway language softens from “beyond Dec 2027” |
| 62% | 35% | Any Stage-3 customer publicly drops; OR Q1 revenue <$50K AND >$20M ATM tranche; OR “delayed” language re: Tier-1 #1 chip return |
What does NOT change the thesis
Calibration aid against narrative drift — items that often feel load-bearing on earnings calls but historically have not moved the LWLG thesis:
- Management tone. LeMaitre’s measured cadence is the baseline; an upbeat-sounding call without a named PO is not new information.
- Generic forward-looking language. “We are well-positioned,” “exciting opportunity,” “robust pipeline” without a numerical anchor — LeMaitre is more disciplined than this, but if Coleman / Q&A elicits softer language, count the metrics, not the adjectives.
- Single foundry mention without quantification. Adding a 5th foundry name with no wafer count, PDK status, or customer pairing = headline only.
- TAM/SAM headline numbers. LightCounting tripled the 1.6T forecast Apr→Oct 2025; LeMaitre will likely cite further upward revisions. Sector-tailwind data does not move LWLG-specific factors.
- Polariton/Marvell commentary in the abstract. Without a direct LWLG-Marvell supply or licensing disclosure, sector-validation language is already priced.
- Reaffirmation of the “2027 first production revenue” line. Identical across Mar 13 2025, Nov 25 2025, Mar 5 2026; reaffirming it is a hold, not a positive.
- R&D vs. G&A reshuffling. FY2025 already showed R&D down 31.5% / G&A up — further mix shifts at constant total OpEx are noise.
- Insider RSU tax-cover sales. Already weekly cadence; only open-market insider buying moves the dial (none YTD 2026 — bear-case input).
- “Engineering capacity is the bottleneck” reaffirmation. Per ECOC Sep 2025; expected, not new.
Sources
kb/05_financials/quarterly_trend.mdx— Q4 2025 print, FY2025 totals, share-count trajectorykb/05_financials/financials_summary.md— cash balance, ATM history, insider activitykb/05_financials/earnings_calls.md— verbatim Mar 5 2026 and Nov 25 2025 quoteskb/05_financials/agm_2026_proxy.md— DEF 14A 4/6/2026 share count 150,610,710kb/06_market_data/atm_filings.md— Apr 21 2026 amendment to $51.4M shelfkb/07_thesis/catalysts.md— May 8 Q1 10-Q catalyst framingsite/src/data/thesis_confidence.json— 5-factor model with current weights, pSuccess, and triggers